Delivering Biotherapeutics to Patients
|
|
- Shauna Kory Cross
- 8 years ago
- Views:
Transcription
1 Delivering Biotherapeutics to Patients UK-PharmSci "The Science of Medicines" East Midland Conference Centre, Nottingham Kevin King 1 September 2010
2 Overview Points to consider in dosage form development of a biotherapeutic Alternative delivery to differentiate a medicine Case study: pre-filled syringe development for a monoclonal antibody
3 Overview Points to consider in dosage form development of a biotherapeutic Alternative delivery to differentiate a medicine Case study: pre-filled syringe development for a monoclonal antibody
4 Points to Consider in BioTx Formulation Clinical and therapeutic needs/requirements Dose, mode/site/duration of action, route of delivery Safe and efficacious Ease of manufacture Molecular Properties Molecular type, Physiochemical properties, PK Stable with suitable shelf life Regulatory requirements Guidelines, specifications, justifications Fileable Marketing Wants! Patent considerations Differentiation, attractiveness Marketable
5 Overview Points to consider in dosage form development of a biotherapeutic Alternative delivery to differentiate a medicine Case study: pre-filled syringe development for a monoclonal antibody
6 Industry Trends Driving Alternative Delivery R&D productivity: life cycle management External pressure for value based healthcare: improved compliance with medicines Emerging markets: multiple, culturally diverse markets Personalised medicines: meeting the needs of specific groups Complex diseases: reduced dosing frequency Rise in biotherapeutics: options to IV/IM/SQ
7 Listening to the Patient. Historically, biologics have been administered parenterally as intravenous or subcutaneous injections, typically in a physician s office or hospital setting Technological innovations have spurred the development of novel delivery approaches (i.e. needle-free, transdermal, inhaled, etc.) Less/non-invasive delivery is an important consideration
8 Formulation, Dosage and Usage Guides the Device Choices BD HyPak Pre-filled syringes Formulation and Primary Packaging Liquid vs. lyophilized Viscosity Existing vs. new Primary Packaging Dosing Route of administration Frequency Volume Fixed vs. variable Home or Clinic Usage Ease of use Patient compliance Genotropin delivery systems Pre-Filled Syringe Pens/Auto-injectors Reconstitution Aids (Lyo vial) Genotropin delivery systems BioJect Recon Adapters
9 Overview Points to consider in dosage form development of a biotherapeutic Alternative delivery to differentiate a medicine Case study: pre-filled syringe development for a monoclonal antibody
10 A Few Monoclonal Facts Monoclonal antibodies (mabs) are relatively stable macromolecules mabs are typically administered at high doses Challenging to develop high concentration formulations for mabs to allow for a more patientfriendly route of administration Challenging, but not impossible Need to accommodate in timeline and $ s 10
11 A Few Monoclonal Facts (continued) SC dosing has lower injection volume requirements Higher the total dose, more challenging it is Ceiling of injection volume means higher protein concentration: potential solubility issues Example: Total dose 100mg, volume 1mL =100mg/ml Doses >/=2-3mg/Kg: new approaches When dose is administered SC need to account for BA Typically 50-80% of IV PD modeling could impact dose Arena for alternate delivery routes is still fairly new and upcoming 11
12 Challenges Formulation and Stability Concentration dependent degradation route of aggregation is the greatest challenge In addition to the potential for non-native protein aggregation and particulate formation, reversible selfassociation may occur Impact to properties such as Viscosity and Delivery by injection Analytical Chromatographic and electrophoretic assays may not be accurate at high protein concentration Sample dilution may result in non-native matrix effect as well as analytical errors 12
13 Challenges (continued) Manufacturing Processes to achieve high concentrations at lab-scale may not be scalable for manufacturing Scale-dependant stress factors play an important role Higher viscosity also complicates manufacturing of high protein concentrations by filtration approaches Another important challenge is lack of large quantities of material to conduct adequate screening and formulation development studies Solution? 13
14 Biologics in Prefilled Syringes Worldwide PFS market size ~1.8 billion units US market growth ~20% per year European market growth ~10% per year Biologics portfolio in prefilled syringes is increasing industrywide Customer Benefits Minimized microbial contamination Reduced medication dosing errors Enhanced convenience and ease of use Market Benefits Reduced therapy and injection costs 2% overfill vs. 23% typical of single does vials Optimized numbers of doses from existing supply 20% API savings vs. vial filling Increased market preference Reference:_http:// acturing/fill_finish/prefilled_syringes.html
15 Development Approach Formulation Development Component Selection Analytical Method Development Manufacture/ Supply Chain Liquid formulation developed for vial presentation Need to optimize for syringes Syringe barrel Needle-type Tip-cap Plunger Analytical methods available for formulation. Syringe-specific methods needed to be developed Type of filling Plunger placement Shipping of supplies
16 Syringe Selection Approach Assortment of PFS components to choose from Barrels: Staked-in needle (SN) vs. Luer tip/lock (LL) Standard vs. Long format Varying volumes Tip-cap/Needle Shield Varying designs Tamper-evident designs Plungers Coated vs. non-coated Packaging format Nested vs. rondo trays
17 Watch-outs Silicone Necessary for syringe functionality Known to have particulate issues with proteins Tungsten Needed to bore the cavity at syringe tip Residual tungsten could lead to stability issues with biologic molecules Glue In case of SN, needed to hold needle in place Could lead to stability issues with formulation
18 PFS Selection Workflow Stage 1: Define needs/wants Stage 2. Gather information from vendors Step 3: Compare options by real-time studies Step 4: Ensure communication between vendor and manufacturer
19 PFS Wish List Minimal to zero silicone on syringe or rubber Baked-on silicone preferred over sprayed-on LL available Staked needle available when silicone is baked on syringe Practically inert stopper to reduce sorptive losses and/or decrease E/L from stopper Compatibility with Tween 20/80 Coated stoppers? When using a staked needle autoclaving is still possible and E/L work is not complicated No particulates or particulate generating syringe system Maintains CCI throughout stability and use period Is simple and easy to fill/process
20 Answers Requested from Vendors Set of syringes that would meet the typical variety of a large clinical portfolio A set of rubber solutions to cover the typical variety of syringe applications Information on how supplier s offers measure up against our wish-list Other emerging technologies or offerings we may have missed on our wish-list Other reasons why we should select the vendors offerings for our standard solution set Technical & Sales Service Level Expectations If Selected
21 Vendor comparisons Component Attribute Silicone-free option Vendor A Yes Vendor B No Vendor C No Baked-on silicone (luer tip only) Yes Yes No Sprayed-on silicone Yes Yes Yes Staked-on needle + Baked-on silicone No No Yes All tip-cap options available Yes Yes Yes Coated plungers available Yes Yes Yes Desired packaging format available No Yes Yes Willingness to work with us/manufacturing site to optimize silicone levels for product Yes Yes Yes Prior manufacturing experience at site with vendor(s) Yes Yes No
22 Plungers and Tip Caps If data in vials available, then see if vendor offers plunger that is comparable to stopper Preservatives in the formulation can Adsorb to the elastomer surface, or Enhance leaching from plunger Many biologic formulations contain surfactants Several examples in literature where surfactants have shown to increase E/L from uncoated rubber stoppers Inert coating may help reduce absorptive losses and/or decrease E/L from the stopper In case where product requires stoppering under special gaseous environment, need to assess permeability of tip-cap for gases
23 Appropriate Sizing of the Container System Large ratio of available rubber surface area : liquid makes E/L from the elastomers a significant concern Relatively low fill volumes may enhance concentration of E/L in solution
24 Molecule Considerations PFS presentation has injection volume restrictions What is the efficacious dose(s)? Is the molecule stable at high concentration? Sensitivity to silicone/tungsten/glue? Tendency to form subvisible and visible particulates? Is any special head-space needed? Syringeability considerations?
25 Formulation Efforts Formulation development for vial presentation was available Goal was to stay with same formulation if possible Injection volume of 1 ml or less was preferred Concentration of vial formulation was sufficient to deliver desired dose in 1 ml Check for container-closure-specific matters: Impact to quality attributes that are specific to the new container closure Difference in process during manufacturing that impact the product attributes Identify process parameters that can be controlled to result in comparable product
26 Silicone: Friend or Foe? Work with vendor to get average silicone levels per barrel (LT & SN) The dispersion of free silicone can be observed by coating the glass surface with silicon carbide powder The sprayed syringe has greater amounts of free silicone Silicone oil droplets are visible in formulations extracted from syringes using light microscopy. Silicone extraction can also be performed
27 Silicone Spiking Studies Use worse-case scenario to define 1x levels Silicone Spiking study: Formulations in vials spiked with 1x, 2x and 3x amount of silicone present in SN barrel 4 Visual appearance results X Silicone Level 2 X Silicone Level 3 X Silicone Level Also conducted a shaking stress study at the silicone spiking levels 300 rpm on orbital shaker No particle formation seen at 5 o C or 25 o C for up to 5 days Months at 5 o C Months at 25 o C
28 Stability Data from Formulation in PFS Majority of product quality attributes remain unchanged between vial and PFS Only differences seen in particulate matter Visible Sub-visible How to ensure that you are seeing the full picture? Reference: mages/clipart/zoo_animals/images/lp_za_f f_img02_elephant.gif
29 Silicone Oil and Sub-Visible Particles Sub-visible particulate matter data obtained after formulations in PFS were subjected to shaking stress 35 Cummulative Particles Cummulative Particles Baked-on Si: 1 ml f ill Baked-on Si: 0.5 ml fill Sprayed-on Si: 1 ml fill Sprayed-on Si: 0.5 ml fill Baked-on Si: Placebo Particles < 25µm Sprayed-on Si: Placebo Particles < 10µm T0 24hr 168hr USP Criteria: < um particles/container <600 25um particles/container T0 24hr 168hr 0 Baked-on Si: 1 ml fill Baked-on Si: 0.5 ml fill Sprayed-on Si: 1 ml fill Sprayed-on Si: 0.5 ml fill Baked-on Si: Placebo Sprayed-on Si: Placebo PFS-type & Fill volume No significant trends or differences between formulations for SN and LL PFS
30 Silicone oil and Sub-visible Particles (contd.) Sub-visible particulate matter data obtained after formulations in PFS were subjected to real time stability study at 5 and 25 o C 25C data indicates particles that are TNTC even at the 3 month time-point HIAC Measurements for SN PFS Formulation at 2-8 o C Cumulative Counts per ml T= 0 T=3M T=6M Particle Size Channel (µm)
31 Visualization of Particles by Light Microscopy Few samples were examined by light microscopy to determine: Nature of the particles causing opalescence Cause of HIAC sensor saturation 100x magnification 100x magnification Too many silicone oil droplets Single amorphous particle (protein?) Oil droplets range from 1 20 µm in diameter
32 Selection of Tip Cap/Needle Shield Although tip cap/needle shield materials are less prone to product contact, it is important to choose the appropriate material. Accelerated stability for the product in contact with material can enhance the understanding and can help to choose the appropriate component % Oxidation Data at 25 C Time (months) Tip Cap 3 was chosen for the product. Control Tip cap 1 Tip cap 2 Tip cap 3 In addition, cracking of tip cap formulation should be evaluated under normal environmental conditions
33 Plunger Movement Concerns for PFS Filled syringes are transported to labeling/packaging sites, clinics, distribution centers, pharmacies, etc Due to a silicone coating in the barrel, there is less friction and the stopper is able to move Plungers can move in pre-filled syringes due to external/internal pressure changes and pressure changes can occur during Air shipment of syringes Travel through high elevation regions Temperature changes Product sterility could be affected if the plunger moves past the second rib of the stopper* (> 5 mm) Product contact 2 nd Rib Barrel Plunger Rod Stopper Tip Cap Reference: Stopper (plunger) movement in syringe systems by Jerome Olivas in PDA conference 2006
34 Challenges to be Addressed As part of product development in syringes, a systematic study was designed to address following questions: Does the plunger move during air transport? How much does the plunger move? Will the plunger come out of the barrel? What is the impact of sterility as well as container closure integrity of a PFS system? What is the effect of the stoppering method (gap)? Is there a difference between sprayed vs. baked on silicone? Staked in needle vs. luer cone syringes Is the movement consistent between various fill volumes? Do we need to design a packaging system which can minimize plunger movement? 5 mm
35 Transportation and Pressure Effects Cargo aircraft Used in most situations Regulated to the same altitude and temperature as commercial aircraft 7,500-8,000 ft and C Cargo Aircraft Feeder aircraft Feeder Aircraft May not be pressurized if cabin has oxygen Maximum flying altitude of 20,000 ft Altitude Above Sea Level (feet) 7,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 Absolute Atmospheric Pressure (Torr) Max altitude (20,000 ft) = 350 Torr = Worst Case Pressure
36 Effect of Stoppering Methods on Air Gap Mechanical stopper placement through insertion tube Stopper is compressed in a narrow tube and placed at a predetermined distance through the use of mechanical plungers Typically results in larger gap Vacuum Stoppering Filled syringes are placed into a unit where a vacuum is applied to place the plungers Results in minimal gap of < 1 mm Vacuum Mechanical Gap 0-1 mm
37 Development of a Lab Scale Model LyoStar II (FTS Smart Lyophilizer) used as a pressure & temperature chamber to simulate various environments Syringes placed in an upright position near a metric ruler Photographs taken to document movement Pressure cycle simulates 2 flights Variables Fill volume 0.4 ml and 1 ml Temperature 5 C and 25 C Pressure ATM (760 Torr) ~300 Torr ATM (760 Torr) Hold Time N/A 18 hours 8 hours Syringe type ~300 Torr 18 hours LC and SN ATM (760 Torr) Minimum of 2 hours Gap 0-1 mm, 1-2 mm, 3-4 mm, and 5-6 mm
38 Development of a Lab Scale Model Feasibility of the use of powder coatings to detect plunger movement Initial positions At 2 Torr Carbon Black Si Carbide Gold Carbon Black Si Carbide Gold Final positions Carbon Black Si Carbide Gold
39 Effect of Air Gap Amount LC PFS with 1 ml fill (4 gaps) 540 Torr: movement begins 415 Torr: some PFS with 5-6 mm gaps have moved past the 2nd rib 320 Torr: PFS with gaps >3 mm have moved past the 2nd rib 760 Torr: stoppers return to initial position
40 Impact of Air Gap on Plunger Movement The linear relationship between gap and plunger movement at various pressures tested can be used to estimate movement 7 Air Gap vs. Plunger Movement Agerage Plunger Movement (mm) Torr 415 Torr 320 Torr y = x y = x y = x Movement past the 2 nd rib of stopper Average Air Gap (mm)
41 Key Take-Away Messages Choice of container closure can impact quality attributes of product Define user requirements early in the program Work with Procurement and Manufacturing to narrow down on component vendors Vendors are in the R&D business as well, and are looking at ways to offer products with better fit You d be surprised at their willingness to work with you! Remember Less is more and Keep it Simple If re-formulating a vial product to PFS, need to minimize changes to the formulation
42 Key Take-Away Messages Increasing number of contact materials increases risks Staked-on needle vs. Luer tip barrel Silicone is required for syringe functionality Some vendors offer silicone-free options Optimize silicone levels to balance product quality vs. functionality Consider sub-visible particulate analysis as a key assay for selection Monitor the lower size ranges (less than 2, 5, 8 µm) Early discussions with Commercial group helps define user requirements Assessment needed to balance needs vs. risks
43 Key Take-Away Messages Work with Supply Chain and Packaging group to identify transport routes Verify container closure integrity during transportation Theoretical equations and models available to calculate plunger movement Experimental approaches are not too difficult to setup in a typical formulation laboratory
44 Road Map of Available Drug Delivery Technologies: 10 yr Outlook Based on Current Information Low MW (<5kDa) Medium MW (5 50kDa) High MW (>50kDa) Delivery Modality Low Dose (<10 mg) Medium Dose (10-30mg) Low Dose (<10mg) Medium Dose (10-30mg) Low Dose (<10mg) Medium Dose (10-30mg) IV/SC (Immediate Release) Now Now Now Now Now Now Depot Injection Now Now Now Now Now 3-5 years Pulmonary Now 3-5 years 2-3 years 3-5 years 3-5 years Unlikely Transdermal 2-3 years Unlikely 2-3 years Unlikely 2-3 years Unlikely Transmucosal 2-3 years >5 years 2-3 years >5 years 3-5 years Unlikely Oral >5 years >5 years >5 years >10 years >5 years >10 years Technology available, but some not optimized Significant technology development required Existing technology options unlikely to delivery
45 Alternate Delivery Modalities What will future BioTx drug products look like? 45
46 Overview Points to consider in dosage form development of a biotherapeutic Alternative delivery to differentiate a medicine Case study: pre-filled syringe development for a monoclonal antibody
47 Acknowledgements Advait Badkar Leigh Bohack Tapan Das Sambit Kar Parag Kolhe Sandeep Nema Vinay Radhakrishnan Amanda Wolf
syriq Glass Prefillable Syringes
syriq Glass Prefillable Syringes 2 SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. With more than 130 years of outstanding development, materials
More informationElastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen. -Senior Manager Biotechnology-
Elastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen -Senior Manager Biotechnology- 2005 by West Pharmaceutical Services, Inc., Lionville, PA All rights reserved.
More informationCompatibility and Physical Stability of Monoclonal Antibodies After Dilution into Different IV Administration Bags
Compatibility and Physical Stability of Monoclonal Antibodies After Dilution into Different IV Administration Bags David Volkin Macromolecule and Vaccine Stabilization Center, Department of Pharmaceutical
More informationIntroduction to Enteris BioPharma
Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based
More informationHow Tight is a Syringe? PDA: A Global. CCI Case Studies From. Association. Development and Manufacturing. Dr. Derek Duncan Director Product Line
How Tight is a Syringe? PDA: A Global CCI Case Studies From Association Development and Manufacturing Dr. Derek Duncan Director Product Line Presentation Outline Setting up syringe CCI studies using laser-based
More informationGUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS
GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS Prepared by Ad Hoc Committee on Nuclear Pharmacy Technicians Nuclear Pharmacy Section Academy of Pharmacy Practice and Management American Pharmaceutical
More informationIN THIS ISSUE. Formulating Happiness. Functional Excipients. OraGuardTM Technology. Atorvastatin ER Tablets. Protecting Intended Action
* DD&D October 2012 Covers_DDT Cover/Back April 2006.qx 9/27/12 2:24 PM Page 2 October 2012 Vol 12 No 8 www.drug-dev.com IN THIS ISSUE INTERVIEW WITH HOVIONE S VP, PARTICLE DESIGN BUSINESS UNIT COLIN MINCHOM,
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationRECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS
RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS After the completion of this module you will be able to: Define medication reconstitution. Read a medication label. Reconstitute a medication. Calculate
More informationPromoting safer use of injectable medicines
Promoting safer use of injectable medicines A template standard operating procedure for: prescribing, preparing and administering injectable medicines in clinical areas Introduction The use of injectable
More informationReconstitution of Solutions
Chapter 12 Reconstitution of Solutions Reconstitution Process of mixing and diluting solutions Some medications supplied in powder form and must be mixed with liquid before administration Parts of Solutions
More informationINSTRUCTION Probemaker
INSTRUCTION Probemaker Instructions for Duolink In Situ Probemaker PLUS (Art. no. 92009-0020) and Duolink In Situ Probemaker MINUS (Art. no. 92010-0020) Table of content 1. Introduction 4 2. Applications
More informationAccelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches
Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches 2008 IBC Formulation Strategies for Protein Therapeutics Tim Kelly, Ph.D.
More informationINCORPORATING IMPROVED TECHNICAL FEATURES IN GLASS PREFILLABLE SYRINGE MANUFACTURING FOR PHARMACEUTICAL USE
INCORPORATING IMPROVED TECHNICAL FEATURES IN GLASS PREFILLABLE SYRINGE MANUFACTURING FOR PHARMACEUTICAL USE Whilst the standard 1ml prefilled glass syringe is now well accepted by the industry with billions
More informationOvercoming Challenges in the Manufacturing of Pre-Filled Syringes. Farvea, a new comer in the PFS world PFS Tech 2016. June 2016 pharma@fareva.
Overcoming Challenges in the Manufacturing of Pre-Filled Syringes Farvea, a new comer in the PFS world PFS Tech 2016 June 2016 pharma@fareva.com Our presence around the world 11 countries 35 sites 12
More informationSterilization methods and equipment Lab 1-2
Sterilization methods and equipment Lab 1-2 PHT 434 Sterilization Sterilization a process that by which all viable M.O are removed or destroyed, based on a probability function. Sterilization concept Sterilization
More informationPHARMACEUTICAL DEVELOPMENT
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL DEVELOPMENT Q8(R2) Current Step
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
European Medicines Agency Inspections London, 17 December 2003 CPMP/QWP/122/02, rev 1 corr COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON STABILITY TESTING: STABILITY TESTING OF EXISTING
More informationMulti-elemental determination of gasoline using Agilent 5100 ICP-OES with oxygen injection and a temperature controlled spray chamber
Multi-elemental determination of gasoline using Agilent 5100 ICP-OES with oxygen injection and a temperature controlled spray chamber Application note Energy & chemicals, petrochemicals Authors Elizabeth
More informationGood practice for the preparation of injectable medicines in clinical areas
Further reading Dougherty L and Lister S (Eds). The Royal Marsden Hospital Manual of Clinical Nursing Procedures (th edition), Blackwell Publishing, Oxford, 00. NMC standards for medicines management (008).
More informationRobert Birdsall, Eoin Cosgrave, Henry Shion, and Weibin Chen Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS
Automating the Determination of Drug-to-Antibody Ratio (DAR) of Antibody Drug Conjugates (ADCs) Based on Separation by Hydrophobic Interaction Chromatography (HIC) Robert Birdsall, Eoin Cosgrave, Henry
More informationGUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS
GUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS 5 th Edition November 2015 NHS Pharmaceutical Quality Assurance Committee 2015 British Oncology Pharmacists Association Pharmaceutical
More informationScanning Electron Microscopy Services for Pharmaceutical Manufacturers
Scanning Electron Microscopy Services for Pharmaceutical Manufacturers Author: Gary Brake, Marketing Manager Date: August 1, 2013 Analytical Testing Laboratory www.atl.semtechsolutions.com Scanning Electron
More informationWestern Blot Analysis with Cell Samples Grown in Channel-µ-Slides
Western Blot Analysis with Cell Samples Grown in Channel-µ-Slides Polyacrylamide gel electrophoresis (PAGE) and subsequent analyses are common tools in biochemistry and molecular biology. This Application
More informationANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS
VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external
More informationHelping to protect you from exposure to hazardous drugs
Helping to protect you from exposure to hazardous drugs Closed system solution: Texium closed male luer and SmartSite needle-free valve products What you can t see can hurt you The risks are well documented
More informationWard 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home
Ward 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home Contents Page Important contact numbers 1 General information on preparing and administering IV antibiotics
More informationParenteral Dosage of Drugs
Chapter 11 Parenteral Dosage of Drugs Parenteral Route of administration other than gastrointestinal Intramuscular (IM) Subcutaneous (SC) Intradermal (ID) IV Parenteral Most medications prepared in liquid
More informationICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products
More informationSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
More informationNIH Clinical Center Patient Education Materials Giving a subcutaneous injection
NIH Clinical Center Patient Education Materials What is a subcutaenous injection? A subcutaneous injection is given in the fatty layer of tissue just under the skin. A subcutaneous injection into the fatty
More informationGuidance for Industry
Guidance for Industry Container Closure Systems for Packaging Human Drugs and Biologics CHEMISTRY, MANUFACTURING, AND CONTROLS DOCUMENTATION U.S. Department of Health and Human Services Food and Drug Administration
More informationAnnex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
World Health Organization WHO Technical Report Series, No. 953, 2009 Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationInstructions for Use. Components of the GENOTROPIN PEN 12
Instructions for Use Important Note Please read these instructions completely before using the GENOTROPIN PEN 12. If there is anything you do not understand or cannot do, call the toll-free number listed
More informationSPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationEDUCATOR S LESSON PLAN
EDUCATOR S LESSON PLAN Pharmacy Technician Training Program Student Version Orientation Orientation introduces the student to basic terms and definitions. An introduction to the Pharmacy Technician Certification
More information= 1.038 atm. 760 mm Hg. = 0.989 atm. d. 767 torr = 767 mm Hg. = 1.01 atm
Chapter 13 Gases 1. Solids and liquids have essentially fixed volumes and are not able to be compressed easily. Gases have volumes that depend on their conditions, and can be compressed or expanded by
More informationSection 2 Solving dosage problems
Section 2 Solving dosage problems Whether your organization uses a bulk medication administration system or a unit-dose administration system to prepare to administer pediatric medications, you may find
More informationTechnical Considerations Detecting Transparent Materials in Particle Analysis. Michael Horgan
Technical Considerations Detecting Transparent Materials in Particle Analysis Michael Horgan Who We Are Fluid Imaging Technology Manufacturers of the FlowCam series of particle analyzers FlowCam HQ location
More information<788> PARTICULATE MATTER IN INJECTIONS
PARTICULATE MATTER IN INJECTIONS Particulate matter in injections and parenteral infusions consists of mobile undissolved particles, other than gas bubbles, unintentionally present in the solutions.
More informationDRUG DOSE CALCULATIONS
FINDING THE ORDERED DOSE The ordered dose is the most simple dosage calculation for the prehospital care provider. In this type of problem, the paramedic is given an order to administer to a patient. There
More informationWashing. Sterilising. Filling. Closing. Inspecting. Labelling
Washing. Sterilising. Filling. Closing. Inspecting. Labelling Washing Page 4/5 Sterilising Page 6/7 Filling Page 8/9, 10/11 Closing Page 8/9, 10/11 Inspecting Page 12/13 Labelling Page 14/15 Syringe processing
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationP.O.N. RICERCA E COMPETITIVITA' 2007-2013 - Azione II "Interventi di sostegno alla ricerca industriale"
P.O.N. Ricerca & Competitività 2007-2013 per le Regioni della convergenza Codice Progetto PON01_02464 cofinanziato a valere sull Asse I - Sostegno ai mutamenti strutturali; Obiettivo operativo 4.1.1.1
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Inspections London, 19 May 2005 CPMP/QWP/4359/03 EMEA/CVMP/205/04 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
More information1-800-862-2731 Administration of Meropenem For Child
1 Drug Name: _Meropenem 1-800-862-2731 Administration of Meropenem For Child Dosage: milligrams every hours over 5 minutes Key Points: FLUSHING: Meropenem Heparin flush 1. Always wash your hands with an
More informationEditorial Calendar 2014
Editorial Calendar 2014 IPI is Peer Reviewed. Please refer to the Editorial Guidelines section on the www.ipimediaworld.com website for Peer Review Protocol and Authors Guidelines. The topics and subjects
More informationInnovative vs Traditional
And in the red corner, introducing the challenger NASDAQ April 4 2011 243.47 $ 1.38 $ 0.58 % 0.07 $ 0.02 $ 39.4 % Technology DVD Digital Streamline Instant Play Internet Access Unlimited Selection No Late
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationA Practical Guide for the selection and use of prefilled Syringes for flushing vascular access devices. Paul Parisien, MedXL inc., Montreal, Canada.
A Practical Guide for the selection and use of prefilled Syringes for flushing vascular access devices. Paul Parisien, MedXL inc., Montreal, Canada. OBJECTIVE The objective of this report is to provide
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationVACUETTE RNAgard Blood Tubes BioMaxi Blood RNA Purification Kit. For the collection, preservation and purification of RNA from whole blood
RNAgard Blood System VACUETTE RNAgard Blood Tubes BioMaxi Blood RNA Purification Kit For the collection, preservation and purification of RNA from whole blood Instructions For Use Protocol blood collection,
More informationMilwaukee USER MANUAL
Milwaukee USER MANUAL PORTABLE DISSOLVED OXYGEN METER MODEL: MW600 Smart DO Meter PROBE PREPARATION: The meter is supplied with a 9V battery. Slide off the battery compartment cover on the back of the
More informationINSTRUCTIONS 56-1190-98. Edition AC
Sephacryl S-100 High Resolution Sephacryl S-200 High Resolution Sephacryl S-300 High Resolution Sephacryl S-400 High Resolution Sephacryl S-500 High Resolution INSTRUCTIONS Sephacryl High Resolution chromatography
More informationParticle Monitoring Requirements in Pharmaceutical Cleanrooms
Particle Monitoring Requirements in Pharmaceutical Cleanrooms All drugs must be manufactured in accordance with the current Good Manufacturing Practice (cgmp) regulations. Pharmaceutical manufacturers
More informationCourse Curriculum for Master Degree in Clinical Pharmacy
Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon
More informationMethod Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates
Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates Paula Hong and Kenneth J. Fountain Waters Corporation, 34 Maple St., Milford, MA, USA APPLICATION
More informationInstructions for Use PROCRIT (PRO KRIT) (epoetin alfa)
Instructions for Use PROCRIT (PROKRIT) (epoetin alfa) Use these Instructions for Use if you or your caregiver has been trained to give PROCRIT injections at home. Do not give yourself the injection unless
More information105 Adopted: 27.07.95
105 Adopted: 27.07.95 OECD GUIDELINE FOR THE TESTING OF CHEMICALS Adopted by the Council on 27 th July 1995 Water Solubility INTRODUCTION 1. This guideline is a revised version of the original Guideline
More informationInstructions. Torpedo sirna. Material. Important Guidelines. Specifications. Quality Control
is a is a state of the art transfection reagent, specifically designed for the transfer of sirna and mirna into a variety of eukaryotic cell types. is a state of the art transfection reagent, specifically
More informationNational Patient Safety Agency. Risk Assessment of Injectable Medicines. STEP 1 Local Risk Factor Assessment. STEP 2 Product Risk Factor Assessment
NPSA Injectable Medicines Risk Assessment Tool National Patient Safety Agency Risk Assessment of Injectable Medicines STEP 1 Local Risk Factor Assessment. Carry out a baseline assessment in a near patient
More informationQuestions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV
Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV The purpose of this document is to provide additional clarification to the existing information
More informationMouse Insulin ELISA. For the quantitative determination of insulin in mouse serum and plasma
Mouse Insulin ELISA For the quantitative determination of insulin in mouse serum and plasma Please read carefully due to Critical Changes, e.g., Calculation of Results. For Research Use Only. Not For Use
More informationHow To Test For Leachables
Current FDA Perspective on Leachable Impurities in Parenteral and Ophthalmic Drug products AAPS Workshop on Pharmaceutical Stability Scientific and Regulatory Considerations for Global Drug Development
More informationICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products. Step 5
European Medicines Agency August 2003 CPMP/ICH/2736/99 ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products Step 5 NOTE FOR GUIDANCE ON STABILITY TESTING: STABILITY TESTING OF NEW
More informationBRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use.
BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. USP proposes the revision and development of a suite of plastic packaging system standards in the current issue of PF. General test chapter
More informationTell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.
SOMAVERT pegvisomant for injection PATIENT INFORMATION SOMAVERT (SOM-ah-vert) (pegvisomant for injection) Read the patient information that comes with SOMAVERT before you start using it and each time you
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
More informationA New Technique Provides Faster Particle Size Analysis at a Lower Cost Compared to Conventional Methods
A New Technique Provides Faster Particle Size Analysis at a Lower Cost Compared to Conventional Methods Howard Sanders and Akshaya Jena Porous Material Inc. Ithaca, NY The technique described here calculates
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationAn introduction to the principles and practice of safe and effective administration of injections
An introduction to the principles and practice of safe and effective administration of injections Introduction Giving an injection safely is considered to be a routine nursing activity. However it requires
More information6 H2O + 6 CO 2 (g) + energy
AEROBIC RESPIRATION LAB DO 2.CALC From Biology with Calculators, Vernier Software & Technology, 2000. INTRODUCTION Aerobic cellular respiration is the process of converting the chemical energy of organic
More informationINJECTION TECHNIQUE. IVF NURSING OFFICE: (301) 400-2151 Darshana (301) 400-2146 Nicole
IVF NURSING OFFICE: (301) 400-2151 Darshana (301) 400-2146 Nicole PLEASE NOTE: If you do not have medications for the next day s dose, you MUST go to the clinic that morning at 6:30 AM for more medications.
More informationInjection molding equipment
Injection Molding Process Injection molding equipment Classification of injection molding machines 1. The injection molding machine processing ability style clamping force(kn) theoretical injection volume(cm3)
More informationCleaning validation of cleanrooms and preparation equipments
Cleaning validation of cleanrooms and preparation equipments Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About Compounding" 23-25 May,
More informationSTOPPERS PREFILLABLE SYRINGE PLUNGERS. The New Definition of High-Quality Components
STOPPERS PREFILLABLE SYRINGE PLUNGERS The New Definition of High-Quality Components Proactively Partnering to Science and Technology West has adopted a continuous verification process that is unrivaled
More informationAnna Serdyuchenko, Victor Gorshelev, Mark Weber John P. Burrows University of Bremen, Institute for Environmental Physics
Anna Serdyuchenko, Victor Gorshelev, Mark Weber John P. Burrows University of Bremen, Institute for Environmental Physics 3-5 June 2013 ACSO meeting WMO Geneva, Switzerland 1 Graphics: DLR-IMF 3-5 June
More informationGuideline for Industry
Guideline for Industry Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products July 1996 ICH Q5C Table of Contents I. INTRODUCTION (1)... 1 II. SCOPE OF THE ANNEX
More informationLearning to Self Inject Methotrexate at Home Developed by Andy Thompson MD FRCPC and Marie J Craig-Chambers B.Sc.Phm
Learning to Self Inject Methotrexate at Home Developed by Andy Thompson MD FRCPC and Marie J Craig-Chambers B.Sc.Phm Why might my Doctor ask me to inject Methotrexate? Methotrexate comes in two forms:
More informationDiffusion and Fluid Flow
Diffusion and Fluid Flow What determines the diffusion coefficient? What determines fluid flow? 1. Diffusion: Diffusion refers to the transport of substance against a concentration gradient. ΔS>0 Mass
More informationFlexi-Q. Elcam Medical s New and Innovative Drug Delivery Devices Animal Study
Flexi-Q Elcam Medical s New and Innovative Drug Delivery Devices Animal Study Written by: Ilana Regev, M.D., David Daily, M.Sc., Biomed. Eng., MBA Elcam Medical Revision 2, December 2014 1 Abstract Biotechnology
More informationIN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION
IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION I. For Calcium Acetate Drug Products Table I.1 Submission Summary * Drug Product Name Strength(s)
More informationPhysical & Chemical Properties. Properties
Physical & Chemical Properties Properties Carbon black can be broadly defined as very fine particulate aggregates of carbon possessing an amorphous quasi-graphitic molecular structure. The most significant
More informationInstructions for Use. TRULICITY (Trū-li-si-tee) (dulaglutide) injection, for subcutaneous use. 0.75 mg/0.5 ml Single-Dose Pen.
Instructions for Use 1 TRULICITY (Trū-li-si-tee) (dulaglutide) injection, for subcutaneous use 0.75 mg/0.5 ml Single-Dose Pen once weekly BREAK SEAL BREAK SEAL Unfold and lay flat Read both sides for full
More informationSTABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS
RESTRICTED STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS Discussions are currently ongoing with the WHO Eastern Mediterranean Region towards a synergistic approach in developing a
More informationDEEPSEALSM SERVICE SOLUTIONS
DEEP WATER CHEMICAL SOLUTIONS DEEPSEALSM SERVICE SOLUTIONS (DEEP SEA ENGINEERING ASSURANCE LEADERSHIP) Solving challenges. Deepwater Solutions from Multi-Chem ABOUT HALLIBURTON Founded in 1919, Halliburton
More informationMark Rohlfing. Vice President of Operations Almac Clinical Services Souderton, Pennsylvania
Mark Rohlfing Vice President of Operations Almac Clinical Services Souderton, Pennsylvania Confidential Almac Group 2014 Who We Are Almac is a global drug development services provider. Our mission is
More informationInsulin Pens & Improving Patient Adherence
Insulin Pens & Improving Patient Adherence Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Kip Benko, MD FACEP Asst Clinical Professor University of Pittsburgh School
More informationGUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION
GUIDELINES GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION Preamble The purpose of this document is to provide guidance for the pharmacist
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationMarken For more information visit: www.marken.com
ceocfointerviews.com All rights reserved! Issue: January 18, 2016 The Most Powerful Name in Corporate News Global Supply Chain Service Provider to the Pharmaceutical and Healthcare Industry We are tracking
More informationBiologic Air-Borne Particle Detection, Sampling, and Identification
Biologic Air-Borne Particle Detection, Sampling, and Identification Introduction The aim of this study was to verify the compatibility of the MesoSystems AirSentinel BioAerosol Sensor and the MesoSystems
More informationHydrogen Sulfide in Petroleum. Mike Nicholson/Tim O BrienO Baker Petrolite Corporation
Hydrogen Sulfide in Petroleum Mike Nicholson/Tim O BrienO Baker Petrolite Corporation Hydrogen Sulfide Toxic, Colorless Gas Rotten Egg Odor Detectable at >10 ppb Paralyzes olfactory system LC50 = 713 ppm
More informationSafe medication. Disposable syringes
Safe medication Disposable syringes Disposable syringes Safe medication Safety, reliability, and accuracy down to the smallest detail as with all other CODAN Products, this commitment also holds true for
More informationDon t Let Money Go to Waste. Learn to Bill Discarded Drugs Correctly.
Don t Let Money Go to Waste. Learn to Bill Discarded Drugs Correctly. The Centers for Medicare & Medicaid Services (CMS) recently released Transmittal 1962 clarifying the use of modifier JW and how to
More informationHow To Store An Acam2000 Vaccine
ACAM2000 Smallpox (Vaccinia) Vaccine, Live Deployment Guidance - Acambis Inc. Revision: October 2008 Information contained in this guidance will also be available through Acambis, in the event that questions,
More informationThe Problem. Enhanced Oil Recovery Research. Research Details. www.equilibar.com. For immediate release: June, 2015
For immediate release: June, 2015 Equilibar Plays Key Role in Research of Enhanced Oil Recovery Using Carbonated Water Flooding Dome loaded regulator holds pressure under extreme testing conditions at
More informationPRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION
SECTION 15: REGULATORY INFORMATION This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations and the MSDS contains all the information required by the
More information